Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. [electronic resource]
Producer: 19950330Description: 244-8 p. digitalISSN:- 0887-6924
- Adult
- Aged
- Antibodies, Monoclonal -- adverse effects
- Antigens, CD -- immunology
- Antigens, Differentiation, Myelomonocytic -- immunology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- analysis
- Cell Differentiation -- drug effects
- Combined Modality Therapy
- Cytarabine -- administration & dosage
- Daunorubicin -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Idarubicin -- administration & dosage
- Immunologic Factors -- therapeutic use
- Leukemia, Promyelocytic, Acute -- mortality
- Life Tables
- Male
- Middle Aged
- Neoplasm Proteins
- Neoplasm, Residual
- Neutropenia -- etiology
- Nuclear Proteins
- Oncogene Proteins, Fusion -- analysis
- Polymerase Chain Reaction
- Promyelocytic Leukemia Protein
- Receptors, Retinoic Acid -- analysis
- Remission Induction
- Salvage Therapy
- Sialic Acid Binding Ig-like Lectin 3
- Survival Analysis
- Transcription Factors -- analysis
- Treatment Outcome
- Tretinoin -- pharmacology
- Tumor Suppressor Proteins
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.